Travere Therapeutics (TVTX) Long-Term Debt Issuances (2013 - 2022)

Travere Therapeutics (TVTX) posted Long-Term Debt Issuances of $316.2 million for Q1 2022, up 14.79% on a QoQ basis from $275.5 million in Q3 2018.

Travere Therapeutics (TVTX) Long-Term Debt Issuances (2013 - 2022) Analysis & Trends

Travere Therapeutics' Long-Term Debt Issuances history runs 7 years deep, the most recent figure standing at $316.2 million for Q1 2022.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to $316.2 million in Q1 2022, while the trailing twelve-month figure through Dec 2022 was $316.2 million (changed N/A YoY) and the FY2022 annual result came in at $316.2 million, changed N/A from the prior year.
Long-Term Debt Issuances was $316.2 million for Q1 2022 at Travere Therapeutics, up from $275.5 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $316.2 million in Q1 2022 and bottomed at $500000.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Travere Therapeutics	5.21 Bn	5.21 Bn	125.25 Mn	-

Download Data